Researchers share results of MVA-BN-respiratory syncytial virus vaccine human challenge trial

By | December 7, 2022
Researchers reported the immunogenicity, efficacy, and safety of the MVA-BN (modified vaccinia Ankara-Bavarian Nordic)-RSV (respiratory syncytial virus) vaccine against RSV-A (RSV subtype A) Memphis 37b strain in a human challenge trial.